Published October 2012 | Version v1
Journal article

Epigenetic inactivation of inhibitor of differentiation 4 (Id4) correlates with prostate cancer

  • 1. Center For Cancer Research and Therapeutics Development, Clark Atlanta University, Atlanta (Georgia)

Description

The inhibitor of DNA-binding (Id) proteins, Id1–4 are negative regulators of basic helix-loop-helix (bHLH) transcription factors. As key regulators of cell cycle and differentiation, expression of Id proteins are increasingly observed in many cancers and associated with aggressiveness of the disease. Of all the four Id proteins, the expression of Id1, Id2, and to a lesser extent, Id3 in prostate cancer and the underlying molecular mechanism is relatively well known. On the contrary, our previous results demonstrated that Id4 acts as a potential tumor suppressor in prostate cancer. In the present study, we extend these observations and demonstrate that Id4 is down-regulated in prostate cancer due to promoter hypermethylation. We used prostate cancer tissue microarrays to investigate Id4 expression. Methylation specific PCR on bisulfite treated DNA was used to determine methylation status of Id4 promoter in laser capture micro-dissected normal, stroma and prostate cancer regions. High Id4 expression was observed in the normal prostate epithelial cells. In prostate cancer, a stage-dependent decrease in Id4 expression was observed with majority of high grade cancers showing no Id4 expression. Furthermore, Id4 expression progressively decreased in prostate cancer cell line LNCaP and with no expression in androgen-insensitive LNCaP-C81 cell line. Conversely, Id4 promoter hypermethylation increased in LNCaP-C81 cells suggesting epigenetic silencing. In prostate cancer samples, loss of Id4 expression was also associated with promoter hypermethylation. Our results demonstrate loss of Id4 expression in prostate cancer due to promoter hypermethylation. The data strongly support the role of Id4 as a tumor suppressor

Availability note (English)

Available from http://dx.doi.org/10.1002/cam4.16; Available from http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3544455

Additional details

Publishing Information

Journal Title
Cancer medicine
Journal Volume
1
Journal Issue
2
Journal Page Range
p. 176-186
ISSN
2045-7634

INIS

Country of Publication
United Kingdom
Country of Input or Organization
International Atomic Energy Agency (IAEA)
INIS RN
46049643
Subject category
S62: RADIOLOGY AND NUCLEAR MEDICINE;
Descriptors DEI
ANDROGENS; CELL CYCLE; DNA; INACTIVATION; LASERS; METHYLATION; NEOPLASMS; POLYMERASE CHAIN REACTION; PROSTATE; TRANSCRIPTION FACTORS
Descriptors DEC
ANDROSTANES; BODY; CHEMICAL REACTIONS; DISEASES; GENE AMPLIFICATION; GLANDS; HORMONES; MALE GENITALS; NUCLEIC ACIDS; ORGANIC COMPOUNDS; ORGANS; PROTEINS; STEROID HORMONES; STEROIDS

Optional Information

Copyright
Copyright (c) 2012 The Authors. Published by Blackwell Publishing Ltd.
Notes
PMCID: PMC3544455; PMID: 23342267; OAI: oai:pubmedcentral.nih.gov:3544455; Re-use of this article is permitted in accordance with the Creative Commons Deed, Attribution 2.5, which does not permit commercial exploitation.